Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04457076 · ClinicalTrials.gov registry record · Phase 3
Evaluation of the Efficacy, Safety, and Tolerability of LevoCept
A Phase 3 study, sponsored by Sebela Women's Health.
- Not yet
- Registry status
- Phase 3
- Development phase
- 1,525
- Enrollment target
NCT04457076: Clinical Trial Phase 3 study, sponsored by Sebela Women's Health.
NCT04457076 is a Phase 3 study that has not yet begun recruiting, run by Sebela Women's Health. The registered enrollment target is 1,525 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04457076, a Phase 3 study, has not yet begun recruiting, sponsored by Sebela Women's Health.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,525 participants
- Enrollment target
Study Summary
To assess the contraceptive efficacy (prevention of pregnancy) of LevoCept
Interventions
- DRUG LevoCept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,525 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2032-06-01 |
| Phase | Phase 3 |
What is known before NCT04457076 opens enrollment
NCT04457076 is an interventional study that assigns participants to a tested intervention. Its 1,525 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% higher).
The record links to 0 conditions, and to 1 intervention - of which LevoCept is the first listed.
NCT04457076 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04457076 about?
NCT04457076 is a clinical study titled "Evaluation of the Efficacy, Safety, and Tolerability of LevoCept". To assess the contraceptive efficacy (prevention of pregnancy) of LevoCept
What is the current status of trial NCT04457076?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 1,525 participants. The study started on 2026-06-01. Estimated completion is 2032-06-01.
What interventions are being tested in trial NCT04457076?
The interventions under investigation include: LevoCept (DRUG).
Who is sponsoring clinical trial NCT04457076?
This trial is sponsored by Sebela Women's Health, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04457076's enrollment target sits among peer trials
1,525 155th of 2000 higher than 1,846 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06257082 · 1,526 participants · NA
Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities
- NCT06876714 · 1,524 participants · Phase 3
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
- NCT06623097 · 1,528 participants · NA
Exercise and Nutrition for Older Cancer Survivors and Their Support Person: The Vitality Study
- NCT06393374 · 1,530 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI